Yokohama, Japan – September 12th, 2024
We are pleased to announce that a research group led by Professor Hiroyuki Eto of the Center for iPS Cell Research and Application (CiRA), Kyoto University, has been selected as the implementing body for the research and development project titled “Development and Practical Application of a Continuous Manufacturing System for High-Quality Artificial Platelets”, proposed under the Key and Advanced Technology R&D through Cross Community Collaboration Program, specifically within the theme “Development and Demonstration of Hemostatic Agent Manufacturing Technologies for Emergency Situations”, publicly solicited by the New Energy and Industrial Technology Development Organization (NEDO).
This project aims to address potential platelet shortages in medical settings during emergencies by developing universal platelets that can be transfused to nearly all patients without rejection.
Minaris Regenerative Medicine Co., Ltd. will contribute by leveraging its CDMO experience and expertise to develop a highly efficient production process for artificial platelets, and to establish a robust manufacturing and quality control system with a view toward social implementation.
- Project Overview
- Project Name:
Key and Advanced Technology R&D through Cross Community Collaboration Program / Development and Demonstration of Hemostatic Agent Manufacturing Technologies for Emergency Situations - R&D Theme:
Development and Practical Application of a Continuous Manufacturing System for High-Quality Artificial Platelets - Consortium Members 1:
- Kyoto University (iPS Cell Research Institute [CiRA] and University Hospital)
- Canon Inc.
- Satake MultiMix Corporation
- Minaris Regenerative Medicine Co., Ltd.
- The Jikei University School of Medicine
- Chiba University
- University of Yamanashi
- Research Period:
FY2024 to FY2028 (planned) - Project Scale:
5 billion yen
1 Professor Eto’s research group will advance technologies for generating platelets from iPS cells. Canon Inc. and Satake MultiMix Corporation will develop manufacturing technologies for the practical application of artificial platelets. Minaris Advanced Therapies will be responsible for establishing manufacturing management and quality assurance systems. The Jikei University School of Medicine will develop models for precise platelet quality evaluation. Chiba University, University of Yamanashi, and Kyoto University will be in charge of clinical trial design and implementation.
About the Project
The Key and Advanced Technology R&D through Cross Community Collaboration Program, implemented by NEDO, promotes research and development of critical technologies that Japan should support from the perspective of securing and strengthening economic security.
This particular initiative focuses on the development of platelet aggregation-promoting agents that activate and efficiently aggregate platelets in the blood, as well as artificial platelets designed for long-term storage. It also aims to develop production technologies and systems for continuous local manufacturing during emergencies, with the goal of practical implementation.
For more details, please refer to the announcement on NEDO’s website:
Decision on the Implementation Structure for the Key and Advanced Technology R&D through Cross Community Collaboration Program / Development and Demonstration of Hemostatic Agent Manufacturing Technologies for Emergency Situations
Consortium Member Links
Kyoto University (iPS Cell Research Institute [CiRA] and University Hospital)
https://www.cira.kyoto-u.ac.jp/
Canon Inc.
https://global.canon/ja/
Satake MultiMix Corporation
https://www.satake.co.jp/
The Jikei University School of Medicine
https://www.jikei.ac.jp/university/
Chiba University
https://www.chiba-u.ac.jp/
University of Yamanashi
https://www.yamanashi.ac.jp/